Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 107

1.

A Sex-Specific MicroRNA-96/5-Hydroxytryptamine 1B Axis Influences Development of Pulmonary Hypertension.

Wallace E, Morrell NW, Yang XD, Long L, Stevens H, Nilsen M, Loughlin L, Mair KM, Baker AH, MacLean MR.

Am J Respir Crit Care Med. 2015 Jun 15;191(12):1432-42. doi: 10.1164/rccm.201412-2148OC.

PMID:
25871906
2.

Oestrogen receptor alpha in pulmonary hypertension.

Wright AF, Ewart MA, Mair K, Nilsen M, Dempsie Y, Loughlin L, Maclean MR.

Cardiovasc Res. 2015 May 1;106(2):206-16. doi: 10.1093/cvr/cvv106. Epub 2015 Mar 12.

PMID:
25765937
3.

Sex affects bone morphogenetic protein type II receptor signaling in pulmonary artery smooth muscle cells.

Mair KM, Yang XD, Long L, White K, Wallace E, Ewart MA, Docherty CK, Morrell NW, MacLean MR.

Am J Respir Crit Care Med. 2015 Mar 15;191(6):693-703. doi: 10.1164/rccm.201410-1802OC.

PMID:
25608111
4.

Transient but not genetic loss of miR-451 is protective in the development of pulmonary arterial hypertension.

Grant JS, Morecroft I, Dempsie Y, van Rooij E, MacLean MR, Baker AH.

Pulm Circ. 2013 Dec;3(4):840-50. doi: 10.1086/674751.

5.

Sex-dependent influence of endogenous estrogen in pulmonary hypertension.

Mair KM, Wright AF, Duggan N, Rowlands DJ, Hussey MJ, Roberts S, Fullerton J, Nilsen M, Loughlin L, Thomas M, MacLean MR.

Am J Respir Crit Care Med. 2014 Aug 15;190(4):456-67. doi: 10.1164/rccm.201403-0483OC.

6.

Endothelial apoptosis in pulmonary hypertension is controlled by a microRNA/programmed cell death 4/caspase-3 axis.

White K, Dempsie Y, Caruso P, Wallace E, McDonald RA, Stevens H, Hatley ME, Van Rooij E, Morrell NW, MacLean MR, Baker AH.

Hypertension. 2014 Jul;64(1):185-94. doi: 10.1161/HYPERTENSIONAHA.113.03037. Epub 2014 Apr 14.

7.

Gender, sex hormones and pulmonary hypertension.

Austin ED, Lahm T, West J, Tofovic SP, Johansen AK, Maclean MR, Alzoubi A, Oka M.

Pulm Circ. 2013 Apr;3(2):294-314. doi: 10.4103/2045-8932.114756. Review.

8.

The first Keystone Symposia Conference on pulmonary vascular isease and right ventricular dysfunction: Current concepts and future therapies.

von Gise A, Archer SL, Maclean MR, Hansmann G.

Pulm Circ. 2013 Apr;3(2):275-7. doi: 10.4103/2045-8932.114751. No abstract available.

9.

Pulmonary arterial hypertension: basis of sex differences in incidence and treatment response.

Mair KM, Johansen AK, Wright AF, Wallace E, MacLean MR.

Br J Pharmacol. 2014 Feb;171(3):567-79. doi: 10.1111/bph.12281. Review.

10.

MicroRNAs in pulmonary arterial remodeling.

Grant JS, White K, MacLean MR, Baker AH.

Cell Mol Life Sci. 2013 Dec;70(23):4479-94. doi: 10.1007/s00018-013-1382-5. Epub 2013 Jun 6. Review.

11.

The influence of gender on the development of pulmonary arterial hypertension.

Dempsie Y, MacLean MR.

Exp Physiol. 2013 Aug;98(8):1257-61. doi: 10.1113/expphysiol.2012.069120. Epub 2013 Apr 26. Review.

PMID:
23625955
12.

Dexfenfluramine and the oestrogen-metabolizing enzyme CYP1B1 in the development of pulmonary arterial hypertension.

Dempsie Y, MacRitchie NA, White K, Morecroft I, Wright AF, Nilsen M, Loughlin L, Mair KM, MacLean MR.

Cardiovasc Res. 2013 Jul 1;99(1):24-34. doi: 10.1093/cvr/cvt064. Epub 2013 Mar 20.

13.

Extended use of dabigatran, warfarin, or placebo in venous thromboembolism.

Schulman S, Kearon C, Kakkar AK, Schellong S, Eriksson H, Baanstra D, Kvamme AM, Friedman J, Mismetti P, Goldhaber SZ; RE-MEDY Trial Investigators; RE-SONATE Trial Investigators.

N Engl J Med. 2013 Feb 21;368(8):709-18. doi: 10.1056/NEJMoa1113697.

14.

Imatinib attenuates hypoxia-induced pulmonary arterial hypertension pathology via reduction in 5-hydroxytryptamine through inhibition of tryptophan hydroxylase 1 expression.

Ciuclan L, Hussey MJ, Burton V, Good R, Duggan N, Beach S, Jones P, Fox R, Clay I, Bonneau O, Konstantinova I, Pearce A, Rowlands DJ, Jarai G, Westwick J, MacLean MR, Thomas M.

Am J Respir Crit Care Med. 2013 Jan 1;187(1):78-89. doi: 10.1164/rccm.201206-1028OC. Epub 2012 Oct 18.

PMID:
23087024
15.

Activity of the estrogen-metabolizing enzyme cytochrome P450 1B1 influences the development of pulmonary arterial hypertension.

White K, Johansen AK, Nilsen M, Ciuclan L, Wallace E, Paton L, Campbell A, Morecroft I, Loughlin L, McClure JD, Thomas M, Mair KM, MacLean MR.

Circulation. 2012 Aug 28;126(9):1087-98. doi: 10.1161/CIRCULATIONAHA.111.062927. Epub 2012 Aug 2.

16.

A role for miR-145 in pulmonary arterial hypertension: evidence from mouse models and patient samples.

Caruso P, Dempsie Y, Stevens HC, McDonald RA, Long L, Lu R, White K, Mair KM, McClure JD, Southwood M, Upton P, Xin M, van Rooij E, Olson EN, Morrell NW, MacLean MR, Baker AH.

Circ Res. 2012 Jul 20;111(3):290-300. doi: 10.1161/CIRCRESAHA.112.267591. Epub 2012 Jun 19.

17.

Endothelium-dependent mechanisms of the vasodilatory effect of the endocannabinoid, anandamide, in the rat pulmonary artery.

Baranowska-Kuczko M, MacLean MR, Kozłowska H, Malinowska B.

Pharmacol Res. 2012 Sep;66(3):251-9. doi: 10.1016/j.phrs.2012.05.004. Epub 2012 May 22.

PMID:
22627170
18.

Gene therapy by targeted adenovirus-mediated knockdown of pulmonary endothelial Tph1 attenuates hypoxia-induced pulmonary hypertension.

Morecroft I, White K, Caruso P, Nilsen M, Loughlin L, Alba R, Reynolds PN, Danilov SM, Baker AH, Maclean MR.

Mol Ther. 2012 Aug;20(8):1516-28. doi: 10.1038/mt.2012.70. Epub 2012 Apr 24.

19.

Development of pulmonary arterial hypertension in mice over-expressing S100A4/Mts1 is specific to females.

Dempsie Y, Nilsen M, White K, Mair KM, Loughlin L, Ambartsumian N, Rabinovitch M, Maclean MR.

Respir Res. 2011 Dec 20;12:159. doi: 10.1186/1465-9921-12-159.

20.

MicroRNA and vascular remodelling in acute vascular injury and pulmonary vascular remodelling.

McDonald RA, Hata A, MacLean MR, Morrell NW, Baker AH.

Cardiovasc Res. 2012 Mar 15;93(4):594-604. doi: 10.1093/cvr/cvr299. Epub 2011 Nov 7. Review.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk